Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FLT3-TKD mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FLT3-ITD mutation (90)

FLT3 mutation (67)

FLT3 D835Y (12)

FLT3 F691L (11)

FLT3-ITD mutation + FLT3-TKD mutation (5)

DNMT3A mutation + FLT3-ITD mutation (4)

FLT3 mutation + NPM1 mutation (4)

FLT3 N676D + FLT3 Y842C (3)

FLT3 mutation + DNMT3A mutation (3)

FLT3 mutation + NRAS mutation (3)

FLT3 wild-type (3)

FLT3-ITD mutation + FLT3 D835 (3)

FLT3-ITD mutation + MLL rearrangement (3)

FLT3-ITD mutation + NPM1 mutation (3)

FLT3‐ITD + NPM1 mutation (3)

FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)

FLT3 mutation + MLL mutation (2)

FLT3-ITD mutation + FLT3 D835Y (2)

FLT3-ITD mutation + FLT3 F691L (2)

FLT3-ITD mutation + IDH1 mutation (2)

FLT3-ITD mutation + IDH2 mutation (2)

FLT3-ITD mutation + WT1 mutation (2)

CEBPZ rearrangement + FLT3-TKD mutation (1)

FLT3 E588_Y589INSKYFYVDFRE (1)

FLT3 F691L + FLT3 D835F (1)

FLT3 F691L + FLT3 D835H (1)

FLT3 F691L + FLT3 D835V (1)

FLT3 F691L + FLT3 D835Y (1)

FLT3 F691L + FLT3 D839G (1)

FLT3 F691L + FLT3 Y842C (1)

FLT3 NPOS + FLT3 D835N (1)

FLT3 V592A + FLT3 D835N (1)

FLT3 V592_D593INSDFREY (1)

FLT3 Y591_V592INSVDFREYE (1)

FLT3 mutation + IDH1 mutation (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3 mutation + PTPN11 mutation (1)

FLT3 positive (1)

FLT3-ITD F692L + NPM1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3‐ITD + DNMT3A mutation (1)

FLT3‐ITD + WT1 mutation (1)

MLL rearrangement + FLT3 mutation (1)

NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)

NPM1 mutation + FLT3-TKD mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3 F691L + FLT3 Y842H (0)

FLT3-ITD F692L (0)

FLT3-ITD mutation (90)

FLT3 mutation (67)

FLT3 D835Y (12)

FLT3 F691L (11)

FLT3-ITD mutation + FLT3-TKD mutation (5)

DNMT3A mutation + FLT3-ITD mutation (4)

FLT3 mutation + NPM1 mutation (4)

FLT3 N676D + FLT3 Y842C (3)

FLT3 mutation + DNMT3A mutation (3)

FLT3 mutation + NRAS mutation (3)

FLT3 wild-type (3)

FLT3-ITD mutation + FLT3 D835 (3)

FLT3-ITD mutation + MLL rearrangement (3)

FLT3-ITD mutation + NPM1 mutation (3)

FLT3‐ITD + NPM1 mutation (3)

FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)

FLT3 mutation + MLL mutation (2)

FLT3-ITD mutation + FLT3 D835Y (2)

FLT3-ITD mutation + FLT3 F691L (2)

FLT3-ITD mutation + IDH1 mutation (2)

FLT3-ITD mutation + IDH2 mutation (2)

FLT3-ITD mutation + WT1 mutation (2)

CEBPZ rearrangement + FLT3-TKD mutation (1)

FLT3 E588_Y589INSKYFYVDFRE (1)

FLT3 F691L + FLT3 D835F (1)

FLT3 F691L + FLT3 D835H (1)

FLT3 F691L + FLT3 D835V (1)

FLT3 F691L + FLT3 D835Y (1)

FLT3 F691L + FLT3 D839G (1)

FLT3 F691L + FLT3 Y842C (1)

FLT3 NPOS + FLT3 D835N (1)

FLT3 V592A + FLT3 D835N (1)

FLT3 V592_D593INSDFREY (1)

FLT3 Y591_V592INSVDFREYE (1)

FLT3 mutation + IDH1 mutation (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3 mutation + PTPN11 mutation (1)

FLT3 positive (1)

FLT3-ITD F692L + NPM1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3‐ITD + DNMT3A mutation (1)

FLT3‐ITD + WT1 mutation (1)

MLL rearrangement + FLT3 mutation (1)

NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)

NPM1 mutation + FLT3-TKD mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3 F691L + FLT3 Y842H (0)

FLT3-ITD F692L (0)

›

Related tests:

LeukoStrat® CDx FLT3 Mutation Assay (6)

LeukoStrat® CDx FLT3 Mutation Assay (6)

FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	HEC73543 Sensitive: C3 – Early Trials HEC73543 Sensitive : C3	HEC73543 Sensitive: C3 – Early Trials HEC73543 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D